Rating Change
HC Wainwright & Co. reiterated its Buy rating on Zenas BioPharma, Inc. (NASDAQ:ZBIO) on October 13, 2026.
reiterateNASDAQ:ZBIO
HC Wainwright & Co. Reiterates Buy Rating on Zenas BioPharma, Inc. (ZBIO)
HC Wainwright & Co. reiterated its Buy rating on Zenas BioPharma, Inc.
At publication ·
What changed
Zenas BioPharma, Inc. (NASDAQ:ZBIO) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $25.42
- Market capitalization
- $1.7B
At a glance
Key takeaways
- HC Wainwright & Co. reiterated a Buy rating on Zenas BioPharma (ZBIO) on October 13, 2026, with the stock trading at $25.41 and a market capitalization of $1.7 billion.
Market Context
Zenas BioPharma, Inc. operates in the Healthcare sector. The stock currently trades at $25.41 with a market capitalization of $1.7B.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Zenas BioPharma, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Zenas BioPharma, Inc.
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 13, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 30, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 30, 2026 | Wedbush | Outperform | N/A |
| Sep 30, 2026 | Citigroup | Buy | N/A |
| Aug 14, 2026 | Wedbush | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View ZBIO Stock Page
Frequently Asked Questions
What does the Buy rating mean for ZBIO?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Zenas BioPharma, Inc. (NASDAQ:ZBIO). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ZBIO forecast page.